Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.

Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF

Arteriosclerosis, thrombosis, and vascular biology5 Apr 2012Cited by 129 (Europe PMC)

PMID22492091DOI10.1161/atvbaha.112.246207PepBankPUB-22492091

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialActivity measurement
In healthy men, exenatide suppressed plasma triglyceride-rich lipoprotein-apolipoprotein B-48 concentration versus placebo.
In plain wordsIn healthy men, exenatide reduced a marker of intestinal blood fat particles compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTRL-apolipoprotein B-48 concentration
Study
n = 15
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 μg · SCAs given in this study (human).
Source sentences
Summary
Exenatide significantly suppressed the plasma concentration and production rate of triglyceride-rich lipoprotein-apolipoprotein B-48, but not of triglyceride-rich lipoprotein-apolipoprotein B-100.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen normolipidemic, normoglycemic men underwent 2 studies each (SC 10 μg exenatide versus placebo), 4 to 6 weeks apart, in random order, in which triglyceride-rich lipoprotein particle kinetics were examined with a primed, constant infusion of deuterated leucine and analyzed by multicompartmenta…
Report a problemFND-2249209101
02HumanRandomized controlled trialActivity measurement
In healthy men, exenatide suppressed triglyceride-rich lipoprotein-apolipoprotein B-48 production versus placebo.
In plain wordsIn healthy men, exenatide reduced production of intestinal blood fat particles compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTRL-apolipoprotein B-48 production
Study
n = 15
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 μg · SCAs given in this study (human).
Source sentences
Summary
Exenatide significantly suppressed the plasma concentration and production rate of triglyceride-rich lipoprotein-apolipoprotein B-48, but not of triglyceride-rich lipoprotein-apolipoprotein B-100.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen normolipidemic, normoglycemic men underwent 2 studies each (SC 10 μg exenatide versus placebo), 4 to 6 weeks apart, in random order, in which triglyceride-rich lipoprotein particle kinetics were examined with a primed, constant infusion of deuterated leucine and analyzed by multicompartmenta…
Report a problemFND-2249209102
03HumanRandomized controlled trialActivity measurement
In healthy men, exenatide did not significantly suppress plasma triglyceride-rich lipoprotein-apolipoprotein B-100 concentration versus placebo.
In plain wordsIn healthy men, exenatide did not significantly reduce this liver-derived blood fat particle marker compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTRL-apolipoprotein B-100 concentration
Study
n = 15
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 μg · SCAs given in this study (human).
Source sentences
Summary
Exenatide significantly suppressed the plasma concentration and production rate of triglyceride-rich lipoprotein-apolipoprotein B-48, but not of triglyceride-rich lipoprotein-apolipoprotein B-100.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen normolipidemic, normoglycemic men underwent 2 studies each (SC 10 μg exenatide versus placebo), 4 to 6 weeks apart, in random order, in which triglyceride-rich lipoprotein particle kinetics were examined with a primed, constant infusion of deuterated leucine and analyzed by multicompartmenta…
Report a problemFND-2249209103
04HumanRandomized controlled trialActivity measurement
In healthy men, exenatide did not significantly suppress triglyceride-rich lipoprotein-apolipoprotein B-100 production versus placebo.
In plain wordsIn healthy men, exenatide did not significantly reduce liver-derived blood fat particle production compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTRL-apolipoprotein B-100 production
Study
n = 15
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 μg · SCAs given in this study (human).
Source sentences
Summary
Exenatide significantly suppressed the plasma concentration and production rate of triglyceride-rich lipoprotein-apolipoprotein B-48, but not of triglyceride-rich lipoprotein-apolipoprotein B-100.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen normolipidemic, normoglycemic men underwent 2 studies each (SC 10 μg exenatide versus placebo), 4 to 6 weeks apart, in random order, in which triglyceride-rich lipoprotein particle kinetics were examined with a primed, constant infusion of deuterated leucine and analyzed by multicompartmenta…
Report a problemFND-2249209104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT01056549

Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans

University Health Network, Toronton = 15Jan 2010 to Sept 2011

Hyperlipidemia

Trial page ClinicalTrials.govUpdated 22 Jun 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.